Idexx Laboratories Inc /De (IDXX) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Idexx Laboratories Inc /De (IDXX) stock forecast summary
Our AI ranks Idexx Laboratories Inc /De outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Idexx Laboratories Inc /De is a large-cap company with a market capitalization of $40.99B. It ranks number 1 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its P/B Ratio of 25.42x is the highest of the 11 peers that report one. Its ROE of 70.7% is the highest of the 11 peers that report one.
A per-ticker accuracy statistic for IDXX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.2%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, IDXX included.
Follow IDXX freeIDXX price chart and AI forecast
How IDXX ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Idexx Laboratories Inc /De (IDXX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | IDXX | Rank |
|---|---|---|
| Market Cap | $40.99B | 1/15 |
| P/E Ratio | 35.97x | – |
| P/B Ratio | 25.42x | 1/11 |
| EPS | $14.23 | – |
| Book Value/Share | $20.47 | – |
| Revenue/Share | $57.80 | – |
| FCF/Share | $15.92 | – |
Profitability & Margins
| Metric | IDXX | Rank |
|---|---|---|
| ROE | 70.7% | 1/11 |
| ROA | 33.1% | 1/13 |
| ROIC | 67.7% | 1/11 |
| Gross Margin | 62.4% | 2/9 |
| Operating Margin | 32.0% | 1/14 |
| Net Margin | 25.0% | 1/11 |
| EBT Margin | 31.3% | 1/14 |
| Tax Rate | 20.0% | – |
Financial Health
| Metric | IDXX | Rank |
|---|---|---|
| Current Ratio | 1.17x | 12/15 |
| Quick Ratio | 0.87x | 7/9 |
| D/E Ratio | 1.13x | 2/12 |
| Financial Leverage | 2.13x | 2/12 |
| Interest Coverage | 8.4x | 4/14 |
| Working Capital | $222M | 6/15 |
Cash Flow
| Metric | IDXX | Rank |
|---|---|---|
| Operating Cash Flow | $1.37B | 1/16 |
| Free Cash Flow | $1.25B | 1/10 |
| Capital Spending | -$117M | 9/10 |
| OCF Growth YoY | 51.4% | 2/5 |
| FCF Growth YoY | 59.9% | – |
| FCF/Sales | 27.6% | 1/10 |
| CapEx/Sales | 2.6% | 8/10 |
Operational Efficiency
| Metric | IDXX | Rank |
|---|---|---|
| Asset Turnover | 1.32x | 1/12 |
| Receivables Turnover | 7.3x | 8/11 |
| Inventory Turnover | 4.4x | 4/9 |
| Fixed Assets Turnover | 6.2x | 3/12 |
| Days Sales Outstanding | 50 days | 4/11 |
| Days Inventory | 84 days | 6/9 |
| Payables Period | 28 days | 8/9 |
| Cash Conversion Cycle | 106 days | 5/8 |
Income Statement
| Metric | IDXX | Rank |
|---|---|---|
| Total Revenue | $4.55B | 1/12 |
| Operating Income | $1.46B | 1/15 |
| Net Income | $1.14B | 1/13 |
| R&D Expense | $261M | 3/16 |
| SG&A Expense | $1.25B | 1/12 |
| Cost of Goods Sold | $1.71B | 1/10 |
Dividend & Shareholder Information
| Metric | IDXX | Rank |
|---|---|---|
| Shares Outstanding | 79M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.51B | 43.9% of assets |
| Cash & Short-term Investments | $197M | 5.7% of assets |
| Accounts Receivable | $627M | 18.2% of assets |
| Inventory | $392M | 11.4% of assets |
| Total Liabilities | $1.83B | 53.2% of assets |
| Short-term Debt | $1.16B | 33.7% of assets |
IDXX quarterly financials and insider trading
Idexx Laboratories Inc /De (IDXX) industry peers
Companies classified under the same SEC industry code as Idexx Laboratories Inc /De (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▶ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| ICCC Immucell Corp /De/ | ▲ | $98M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| VNRX Volitionrx Ltd | ▼ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Where IDXX sits on the market map
Idexx Laboratories Inc /De (IDXX) stock news
Loading...
Idexx Laboratories Inc /De (IDXX) stock forecast FAQ
What is the Idexx Laboratories Inc /De (IDXX) stock forecast?
Our AI ranks Idexx Laboratories Inc /De outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Idexx Laboratories Inc /De stock predictions?
A per-ticker accuracy statistic for IDXX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Idexx Laboratories Inc /De forecasts updated?
Idexx Laboratories Inc /De forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Idexx Laboratories Inc /De's industry peers?
17 issuers in our coverage, IDXX included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL), Achieve Life Sciences, Inc. (ACHV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.